Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1130595
Abstract: Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and… read more here.
Keywords: safety; zanubrutinib treatment; lymphoid malignancies; zanubrutinib ... See more keywords